FDA Approves Merck’s Once-Daily Idvynso Tablet Combining Doravirine and Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

The Food and Drug Administration has approved Idvynso, a once-daily, two-drug tablet manufactured by Merck, for the treatment of HIV-1 infection in adults. This new medication is intended for individuals who have already achieved virologic suppression on a stable antiretroviral regimen.

Idvynso combines doravirine and islatravir into a single tablet, simplifying the treatment regimen for appropriate patients. The FDA’s approval allows adults with HIV-1, who have a suppressed viral load (HIV-1 RNAn

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 1, 2026

Author

GOAI